Who makes Irinotecan-only and sequential-CMAB009?

Irinotecan-only and sequential-CMAB009 is developed by Shanghai Zhangjiang Biotechnology Limited Company.

What development phase is Irinotecan-only and sequential-CMAB009 in?

Irinotecan-only and sequential-CMAB009 is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Shanghai Zhangjiang Biotechnology Limited Company · Phase 2 active Small molecule

Generic name	Irinotecan-only and sequential-CMAB009
Also known as	YiMaiLin for irinotecan
Sponsor	Shanghai Zhangjiang Biotechnology Limited Company
Modality	Small molecule
Phase	Phase 2

No approved indications tracked.

No common side effects on file.

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results